Sweden virus covid-19 pneumonia Sweden

Medivir and SciLifeLab partner to identify Covid-19 drug candidates

Reading now: 819
www.pharmaceutical-technology.com

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Swedish drug development company Medivir has partnered with SciLifeLab, a life science research firm, to identify compounds with the potential to inhibit SARS-CoV-2, the novel coronavirus that causes Covid-19.

The research collaboration will involve SciLifeLab’s Drug Discovery and Development Platform (DDD), which will gain access to Medivir’s protease-targeted compound library.

As part of the collaboration, the partners will work to identify the main protease of SARS CoV-2, Mpro, an essential non-structural protein needed for virus replication.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA